Newest Valeant Ally Plays Up Investor Muscle In M&A Fights
Valeant Pharmaceuticals International Inc.'s hostile $53 billion push for Allergan Inc. took a promising turn after a supportive hedge fund reportedly bought into the reluctant target, the latest reminder that zealous...To view the full article, register now.
Already a subscriber? Click here to view full article